MAVENIR
15.12.2022 08:01:32 CET | Business Wire | Press release
Mavenir today announces the completion of radio integration at the Joint European O-RAN and TIP PlugFest, part of the O-RAN Global PlugFest Fall 2022, at the i14yLab in Berlin, hosted by Deutsche Telekom, EANTC and Vodafone. Mavenir validated its massive MIMO (mMIMO) 32TRX Active Antenna Unit (AAU) for open integration with the Keysight Technologies O-RU conformance and certification testing solution.
Mavenir’s OpenBeam mMIMO 32TRX AAU, is a high-performance O-RAN based Radio Unit (O-RU) supporting 400Mhz instantaneous bandwidth and 200 Mhz occupied bandwidth to meet high capacity and RAN sharing use cases. At 16.8kg, utilizing just passive cooling technology, it is one of industry’s lightest AAU, with uncompromising performance delivering 240W output power and high bandwidth. The AAU utilizes Zero-Force Beamforming technology to maximize performance while minimizing interference.
BG Kumar, President of Mavenir’s Access Networks, Platforms and MDE, said, “Mavenir has further strengthened the Open RAN ecosystem by introducing a competitive, high performance 32TRX mMIMO AAU O-RU product. Through the successful integration and testing at the PlugFest in Berlin, Mavenir aims to accelerate the adoption of open, disaggregated and standards-based solutions.”
Mavenir demonstrated the 32TRX AAU at PlugFest using Keysight’s Open RAN Studio Open RAN Distributed Unit (O-DU) emulator, VXT PXI Vector Transceiver, MXA/MXG signal generators, and PathWave Test Automation framework.
The 32TRX mMIMO AAU is part of the OpenBeam portfolio featuring energy efficiency capabilities, delivering savings of over 80% power consumption during idle periods. It also reduces Total Cost of Ownership (TCO) by employing AI/ML based intelligent automation for fault management, beamforming, energy efficiency, load balancing and improved network performance when used as part of Mavenir’s Open vRAN Solution. Initial 32TRX mMIMO AAU products launched this year cover 3.3GHz to 3.8GHz, targeting Europe, the Americas, and South-East Asia.
In addition to the massive MIMO AAU showcased for integration at the PlugFest, the OpenBeam O-RU portfolio also includes mmWave AAUs and multi-band RRUs for improved network capacity. The OpenBeam O-RUs are available across all frequency bands and can be used for a wide range of use cases, including enterprise and public networks for urban or rural environments.
Mavenir’s participation at the PlugFest builds upon ongoing engagements and progresses current activity in the region. Earlier in the year, Mavenir expanded its European capabilities with the establishment of an Open RAN Centre of Excellence in Germany, strengthening Mavenir’s multinational organisation by delivering regional focus, driving the knowledge and innovation across the region.
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers.
i14yLab
The i14y Lab is an open lab for interoperability testing of disaggregated telco systems, such as Open RAN. The lab is operated by a consortium of strong academic and industry partners led by Deutsche Telekom and supported with funding from the German Ministry of Digital and Transport (BMDV).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005908/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom